[go: up one dir, main page]

DK3789501T3 - Fremgangsmåde til diagnosticering, behandling og forebyggelse af parkinsons sygdom - Google Patents

Fremgangsmåde til diagnosticering, behandling og forebyggelse af parkinsons sygdom Download PDF

Info

Publication number
DK3789501T3
DK3789501T3 DK20203903.8T DK20203903T DK3789501T3 DK 3789501 T3 DK3789501 T3 DK 3789501T3 DK 20203903 T DK20203903 T DK 20203903T DK 3789501 T3 DK3789501 T3 DK 3789501T3
Authority
DK
Denmark
Prior art keywords
parkinson
diagnosing
disease
prevention
procedure
Prior art date
Application number
DK20203903.8T
Other languages
English (en)
Inventor
Filip Scheperjans
Petri Auvinen
Velma Aho
Pedro Pereira
Kaisa Koskinen
Lars Paulin
Original Assignee
Neurobiome Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurobiome Oy filed Critical Neurobiome Oy
Application granted granted Critical
Publication of DK3789501T3 publication Critical patent/DK3789501T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
DK20203903.8T 2014-05-28 2015-05-28 Fremgangsmåde til diagnosticering, behandling og forebyggelse af parkinsons sygdom DK3789501T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20145492A FI127671B (en) 2014-05-28 2014-05-28 Procedure for the diagnosis of Parkinson's disease
EP15798909.6A EP3149205B1 (en) 2014-05-28 2015-05-28 Method for diagnostics, treatment and prevention of parkinson's disease

Publications (1)

Publication Number Publication Date
DK3789501T3 true DK3789501T3 (da) 2024-03-04

Family

ID=54698167

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20203903.8T DK3789501T3 (da) 2014-05-28 2015-05-28 Fremgangsmåde til diagnosticering, behandling og forebyggelse af parkinsons sygdom

Country Status (6)

Country Link
US (4) US10139408B2 (da)
EP (2) EP3789501B1 (da)
DK (1) DK3789501T3 (da)
ES (1) ES2972858T3 (da)
FI (2) FI127671B (da)
WO (1) WO2015181449A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104768560A (zh) 2012-08-29 2015-07-08 加州理工学院 孤独症谱系障碍的诊断和治疗
WO2016069801A1 (en) 2014-10-30 2016-05-06 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodecelopmental disorders
KR20170086492A (ko) 2014-10-30 2017-07-26 캘리포니아 인스티튜트 오브 테크놀로지 신경발달 장애에서의 행동을 개선시키기 위한 박테리아를 포함하는 조성물 및 방법
CN106974940B (zh) * 2016-01-15 2020-08-25 深圳华大生命科学研究院 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
EP3465212A4 (en) * 2016-05-23 2020-01-08 California Institute of Technology REGULAR FLORAL REGULATION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
KR101944664B1 (ko) * 2017-02-24 2019-02-01 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 파킨슨병 진단방법
EP3369423A1 (en) 2017-03-01 2018-09-05 Reminisciences Synbiotic composition and its use for preventing and/or treating neurodegenerative disorders
US11147792B2 (en) 2017-05-15 2021-10-19 Axial Therapeutics, Inc. Inhibitors of microbially induced amyloid
WO2018212288A1 (ja) * 2017-05-18 2018-11-22 株式会社ヤクルト本社 パーキンソン病の判定マーカーおよび判定方法
DE102017111547A1 (de) * 2017-05-26 2018-11-29 Aiden Haghikia Mittel zur Behandlung von Erkrankungen mit Mikrobiom-Bezug
SG11201911984QA (en) * 2017-09-29 2020-01-30 Univ Industry Cooperation Group Kyung Hee Univ Novel lactic acid bacteria and use thereof
KR102130485B1 (ko) * 2017-10-13 2020-07-06 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 알츠하이머치매 진단방법
WO2019200398A1 (en) * 2018-04-13 2019-10-17 Dana-Farber Cancer Institute, Inc. Ultra-sensitive detection of cancer by algorithmic analysis
WO2020214538A1 (en) * 2019-04-17 2020-10-22 Aztherapies, Inc Treatment and prevention of dementia and other neurodegenerative diseases
US20220340955A1 (en) * 2019-09-19 2022-10-27 Ramot At Tel-Aviv University Ltd. Methods for diagnosing and treatment monitoring of adnp-deficient patients
US20230384327A1 (en) * 2019-12-23 2023-11-30 Albert-Ludwigs-Universitat Freiburg Gut microbiota-related methods for treating dementia and age-dependent cognitive decline
EP3879272A1 (en) * 2020-03-09 2021-09-15 Albert-Ludwigs-Universität Freiburg Gut microbiota-related methods for treating dementia and age-dependent cognitive decline
WO2023094733A1 (en) 2021-11-29 2023-06-01 Neurobiome Oy Method for treatment and prevention of parkinson's disease
CN117363763A (zh) * 2023-11-02 2024-01-09 美益添生物医药(武汉)有限公司 一种与功能性便秘相关的微生物标志物组合及其应用
CN119614730A (zh) * 2025-02-17 2025-03-14 美益添生物医药(武汉)有限公司 一种与帕金森综合征相关的肠道菌群标志物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20020013270A1 (en) * 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040062757A1 (en) 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8617536B2 (en) 2009-10-30 2013-12-31 Mayo Foundation For Medical Education And Research Prevotella histicola preparations and the treatment of autoimmune conditions
WO2013036290A1 (en) * 2011-09-09 2013-03-14 Yale University Compositions and methods for assessing and treating inflammatory diseases and disorders
CA2850437A1 (en) 2011-10-11 2013-04-18 Achim Biotherapeutics Ab Composition comprising anaerobically cultivated human intestinal microbiota
WO2013056222A1 (en) * 2011-10-14 2013-04-18 New York University Causative agents and diagnostic methods relating to rheumatoid arthritis
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
EP2863929B1 (en) 2012-06-22 2016-07-20 Nestec S.A. Probiotic and polyphenol against neurodegeneration
NZ711771A (en) 2013-02-04 2016-11-25 Seres Therapeutics Inc Compositions for treating or preventing or reducing the severity of clostridium difficile related diseases
ES2692162T3 (es) * 2013-06-03 2018-11-30 Proprev Ab Tratamiento de obesidad, síndrome metabólico, diabetes tipo 2, enfermedades cardiovasculares, demencia, enfermedad de Alzheimer y enfermedad inflamatoria intestinal usando al menos una cepa bacteriana de Prevotella

Also Published As

Publication number Publication date
EP3149205A1 (en) 2017-04-05
EP3149205A4 (en) 2018-02-21
US20190137493A1 (en) 2019-05-09
US20170191998A1 (en) 2017-07-06
US10139408B2 (en) 2018-11-27
US11906517B2 (en) 2024-02-20
US20210109098A1 (en) 2021-04-15
US20230221314A1 (en) 2023-07-13
FI20145492A (fi) 2015-11-29
ES2972858T3 (es) 2024-06-17
FI3789501T3 (fi) 2024-02-26
EP3789501A1 (en) 2021-03-10
EP3149205B1 (en) 2020-11-18
EP3789501B1 (en) 2023-12-20
FI127671B (en) 2018-11-30
WO2015181449A1 (en) 2015-12-03
US11499971B2 (en) 2022-11-15

Similar Documents

Publication Publication Date Title
DK3789501T3 (da) Fremgangsmåde til diagnosticering, behandling og forebyggelse af parkinsons sygdom
IL285114A (en) Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
DK3386511T3 (da) Fremgangsmåder til behandling af huntingtons sygdom
DK3340981T3 (da) Aryl, heteroaryl og heterocykliske forbindelser til behandling af medicinske forstyrrelser
DK3360508T3 (da) Hjælpeanordning til dental behandling
EP3601536A4 (en) TREATMENT PROCESSES
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
HUE052095T2 (hu) Keratin kezelési készítmények és eljárások
DK3277815T3 (da) Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser
DK3442580T3 (da) Fremgangsmåder til behandling af kolestatiske og fibrotiske sygdomme
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK2968218T3 (da) Kombination til behandling af parkinsons sygdom
DK3204386T3 (da) Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
DK3209696T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3463351T3 (da) Behandling til parkinsons sygdom
DK3467111T3 (da) LNCRNAS til terapi og diagnose af hjertehypertrofi
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3294345T3 (da) Tpp1-formuleringer og fremgangsmåder til behandling af cln2-sygdom
IL256103B (en) Compositions and methods for treating celiac sprue disease
DK3224354T3 (da) Manipulerede iminreductaser og fremgangsmåder til den reduktive aminering af keton- og aminforbindelser
DK3389669T3 (da) Triterpensaponinvarianter, syntesefremgangsmåder og anvendelse deraf
DK3157522T3 (da) Muskarin-antagonister og kombinationer deraf til behandlingen af luftvejssygdomme i heste
DK3439661T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3209295T3 (da) Fremgangsmåder til behandling af øjenlidelser